~~<i id='172DD6A7B7'><strike id='172DD6A7B7'><tt id='172DD6A7B7'><pre id='172DD6A7B7'></pre></tt></strike></i>~~

Home» comprehensive» explore

explore

author：knowledge 2025-09-06 09:54:28 Page View：57238

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What AstraZeneca
Next article： Hepatitis C has a cure — but many Americans still lack access to it

Wikipedia

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

Study: Pain burden is higher in Black NFL players than white ones

JuliusThomas,nowpursuinghisPh.D.inpsychology,playingfortheMiamiDolphinsin2017.AdrianKraus/APIt’stobe

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

China demands US invite Hong Kong leader to economic meeting, adding to strains over crackdown

FILE-HongKong'sChiefExecutiveJohnLeegivesaspeechfollowingaswearing-inceremonytoinauguratethecity'sne